{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-001958","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.667381+00:00","generated_at":"2026-05-24T05:53:26.604676+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioNexus Gene Lab shareholders approve reverse stock split at 1:5 to 1:10 ratio","bullets":["98.36% of votes cast (4.94B) approved reverse stock split; ratio range of 1:5 to 1:10 at Board discretion.","Series Z Preferred Stock with 5B votes mirrored common stock votes exclusively for this proposal.","Adjournment proposal also passed with 98.60% approval.","Special Meeting held March 19, 2025; no other matters voted."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-001958","json":"https://secwatch.observer/filing/0001477932-25-001958.json","markdown":"https://secwatch.observer/filing/0001477932-25-001958.md","text":"https://secwatch.observer/filing/0001477932-25-001958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225001958/0001477932-25-001958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225001958/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:53:26.604676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}